Docking and quantitative structure-activity relationship of oxadiazole derivates as inhibitors of GSK3 \upbeta β

Molecular Diversity

Volumn 18, Issue 1, 2014, Pages 149-159

  Quesada Romero, Luisa ^a   Caballero, Julio ^a  

^a UNIVERSIDAD DE TALCA   (Chile)

Author keywords

Docking; GSK3 upbeta inhibitors; Optimal descriptors; Oxadiazole derivates; Quantitative structure activity relationships; Three dimensional descriptors

Indexed keywords

COMPUTER SIMULATION; GLYCOGEN SYNTHASE KINASE 3; MOLECULAR DOCKING SIMULATION; OXADIAZOLES; PROTEIN CONFORMATION; PROTEIN KINASE INHIBITORS; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84894046901     PISSN: 13811991     EISSN: 1573501X     Source Type: Journal    
DOI: 10.1007/s11030-013-9483-5     Document Type: Article

References (37)

1. Ballard C, Gauthier S, Corbett A, Brayne C, Aarsland D, Jones E (2011) Alzheimer's disease. Lancet 377:1019-1031. doi: 10.1016/S0140-6736(10)61349-9
2. Stoothoff WH, Johnson GV (2005) Tau phosphorylation: physiological and pathological consequences. Biochim Biophys Acta 1739:280-297. doi: 10.1016/j.bbadis.2004.06.017
3. Wagner U, Utton M, Gallo JM, Miller CC (1996) Cellular phosphorylation of tau by GSK-3 beta influences tau binding to microtubules and microtubule organisation. J Cell Sci 109:1537-1543
4. Eldar-Finkelman H, Licht-Murava A, Pietrokovski S, Eisenstein M (2010) Substrate competitive GSK-3 inhibitors: strategy and implications. Biochim Biophys Acta 1804:598-603. doi: 10.1016/j.bbapap.2009.09.010
5. Bertrand JA, Thieffine S, Vulpetti A, Cristiani C, Valsasina B, Knapp S, Kalisz HM, Flocco M (2003) Structural characterization of the GSK-3[beta] active site using selective and non-selective ATP-mimetic inhibitors. J Mol Biol 333:393-407. doi: 10.1016/j.jmb.2003.08.031
6. Ryves WJ, Harwood AJ (2001) Lithium inhibits glycogen synthase kinase-3 by competition for magnesium. Biochem Biophys Res Commun 280:720-725. doi: 10.1006/bbrc2000.4169
7. Caballero J, Zilocchi S, Tiznado W, Collina S, Rossi D (2011) Binding studies and quantitative structure-activity relationship of 3-amino-1H-indazoles as inhibitors of GSK3beta. Chem Biol Drug Des 78:631-641. doi: 10.1111/j.1747-0285.2011.01186.x
8. Lo Monte F, Kramer T, Gu J, Anumala UR, Marinelli L, La Pietra V, Novellino E, Franco B, Demedts D, Van Leuven F, Fuertes A, Dominguez JM, Plotkin B, Eldar-Finkelman H, Schmidt B (2012) Identification of glycogen synthase kinase-3 inhibitors with a selective sting for glycogen synthase kinase-3alpha. J Med Chem 55:4407-4424. doi: 10.1021/jm300309a
9. Lo Monte F, Kramer T, Gu J, Brodrecht M, Pilakowski J, Fuertes A, Dominguez JM, Plotkin B, Eldar-Finkelman H, Schmidt B (2013) Structure-based optimization of oxadiazole-based GSK-3 inhibitors. Eur J Med Chem 61:26-40. doi: 10.1016/j.ejmech.2012.06.006
10. Alzate-Morales JH, Vergara-Jaque A, Caballero J (2010) Computational study on the interaction of N1 substituted pyrazole derivatives with B-Raf kinase: an unusual water wire hydrogen-bond network and novel interactions at the entrance of the active site. J Chem Inf Model 50:1101-1112. doi: 10.1021/ci100049h
11. Alzate-Morales JH, Caballero J, Vergara-Jaque A, González-Nilo FD (2009) Insights into the structural basis of N-2 N 2 and O-6 O 6 substituted guanine derivatives as cyclin-dependent kinase 2 (CDK2) inhibitors: prediction of the binding modes and potency of the inhibitors by docking and ONIOM calculations. J Chem Inf Model 49:886-899. doi: 10.1021/ci8004034
12. Muñoz C, Adasme F, Alzate-Morales JH, Vergara-Jaque A, Kniess T, Caballero J (2012) Study of differences on the VEGFR2 inhibitory activities between semaxanib and SU5205 by using 3D-QSAR, docking, and molecular dynamics simulations. J Mol Graph Model 32:39-48. doi: 10.1016/j.jmgm.2011.10.005
13. Caballero J, Quiliano M, Alzate-Morales JH, Zimic M, Deharo E (2011) Docking and quantitative structure-activity relationship studies for 3-fluoro-4-(pyrrolo[2,1-f][1,2,4]triazin-4-yloxy)aniline, 3-fluoro-4-(1H- pyrrolo[2,3-b]pyridin-4-yloxy)aniline, and 4-(4-amino-2-fluorophenoxy)-2- pyridinylamine derivatives as c-Met kinase inhibitors. J Comput Aided Mol Des 25:349-369. doi: 10.1007/s10822-011-9425-1
14. Caballero J, Munoz C, Alzate-Morales JH, Cunha S, Gano L, Bergmann R, Steinbach J, Kniess T (2012) Synthesis, in silico, in vitro, and in vivo investigation of 5-[(1)(1)C]methoxy-substituted sunitinib, a tyrosine kinase inhibitor of VEGFR-2. Eur J Med Chem 58:272-280. doi: 10.1016/j.ejmech.2012.10. 020
15. Caballero J, Zilocchi S, Tiznado W, Collina S (2012) Docking and quantitative structure-activity relationship studies for imidazo[1,2-a]pyrazines as inhibitors of checkpoint kinase-1. Med Chem Res 21:1912-1920. doi: 10.1007/s00044-011-9714-1
16. Caballero J, Alzate-Morales JH (2012) Molecular dynamics of protein kinase-inhibitor complexes: a valid structural information. Curr Pharm Des 18:2946-2963. doi: 10.2174/138161212800672705
17. Caballero J, Alzate-Morales JH, Vergara-Jaque A (2011) Investigation of the differences in activity between hydroxycycloalkyl N1 substituted pyrazole derivatives as inhibitors of B-Raf kinase by using docking, molecular dynamics, QM/MM, and fragment-based De novo design: study of binding mode of diastereomer compounds. J Chem Inf Model 51:2920-2931. doi: 10.1021/ci200306w
18. Friesner RA, Banks JL, Murphy RB, Halgren TA, Klicic JJ, Mainz DT, Repasky MP, Knoll EH, Shelley M, Perry JK, Shaw DE, Francis P, Shenkin PS (2004) Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. J Med Chem 47:1739-1749. doi: 10.1021/jm0306430
19. Schrödinger (2007) Maestro, version 9.0, 2007. Schrödinger LLC, New York
20. Saitoh M, Kunitomo J, Kimura E, Hayase Y, Kobayashi H, Uchiyama N, Kawamoto T, Tanaka T, Mol CD, Dougan DR, Textor GS, Snell GP, Itoh F (2009) Design, synthesis and structure-activity relationships of 1,3,4-oxadiazole derivatives as novel inhibitors of glycogen synthase kinase-3beta. Bioorg Med Chem 17:2017-2029. doi: 10.1016/j.bmc.2009.01.019
21. Schrödinger (2009) Ligprep, version 2.3. Schrödinger LLC, New York
22. Todeschini R, Consonni V, Pavan M (2002) Dragon software version 2.1. Talete SRL, Milan
23. Hemmer MC, Gasteiger J (2000) Prediction of three-dimensional molecular structures using information from infrared spectra. Anal Chim Acta 420:145-154. doi: 10.1016/S0003-2670(00)00876-X
24. Hemmer MC, Steinhauer V, Gasteiger J (1999) Deriving the 3D structure of organic molecules from their infrared spectra. Vib Spectr 19:151-164. doi: 10.1016/S0924-2031(99)00014-4
25. Schuur JH, Selzer P, Gasteiger J (1996) The coding of the three-dimensional structure of molecules by molecular transforms and its application to structure-spectra correlations and studies of biological activity. J Chem Inf Comput Sci 36:334-344. doi: 10.1021/ci950164c
26. Todeschini R, Lasagni M, Marengo E (1994) New molecular descriptors for 2D and 3D structures. Theory J Chemom 8: 263-272. doi: 10.1002/cem.1180080405
27. Consonni V, Todeschini R, Pavan M (2002) Structure/response correlations and similarity/diversity analysis by getaway descriptors. 1. Theory of the novel 3D molecular descriptors. J Chem Inf Comput Sci 42:682-692. doi: 10.1021/ci015504a
28. Benfenati E, Toropov AA, Toropova AP, Manganaro A (2011) Coral software: QSAR for anticancer agents. Chem Biol Drug Des 77:471-476. doi: 10.1111/j.1747-0285.2011.01117.x
29. Toropova AP, Toropov AA, Diaza RG, Benfenati E, Gini G (2011) Analysis of the co-evolutions of correlations as a tool for QSAR-modeling carcinogenicity: an unexpected good prediction based on a model that seems untrustworthy. Cent Eur J Chem 9:165-174. doi: 10.2478/s11532-010-0135-7
30. Toropov AA, Toropova AP, Martyanov SE, Benfenati E, Gini G, Leszczynska D, Leszczynski J (2011) Comparison of SMILES and molecular graphs as the representation of the molecular structure for QSAR analysis for mutagenic potential of polyaromatic amines. Chem Intel Lab Syst 109:94-100. doi: 10.1016/j.chemolab.2011.07.008
31. Toropova AP, Toropov AA, Benfenati E, Gini G, Leszczynska D, Leszczynski J (2011) CORAL: quantitative structure-activity relationship models for estimating toxicity of organic compounds in rats. J Comput Chem 32:2727-2733. doi: 10.1002/jcc.21848
32. Guha R, Howard MT, Hutchison GR, Murray-Rust P, Rzepa H, Steinbeck C, Wegner J, Willighagen EL (2006) The Blue ObeliskInteroperability in chemical informatics. J Chem Inf Model 46:991-998. doi: 10.1021/ci050400b
33. Cronin MTD, Schultz TW (2003) Pitfalls in QSAR. J Mol Struct THEOCHEM 622:39-51. doi: 10.1016/S0166-1280(02)00616-4
34. Fernandez M, Carreiras MC, Marco JL, Caballero J (2006) Modeling of acetylcholinesterase inhibition by tacrine analogues using Bayesian-regularized genetic neural networks and ensemble averaging. J Enzyme Inhib Med Chem 21:647-661. doi: 10.1080/14756360600862366
35. Golbraikh A, Tropsha A (2002) Beware of q2!. J Mol Graph Model 20:269-276. doi: 10.1016/S1093-3263(01)00123-1
36. Roy PP, Roy K (2009) QSAR studies of CYP2D6 inhibitor aryloxypropanolamines using 2D and 3D descriptors. Chem Biol Drug Des 73:442-455. doi: 10.1111/j.1747-0285.2009.00791.x
37. Ojha PK, Mitra I, Das RN, Roy K (2011) Further exploring rm2 metrics for validation of QSPR models. Chem Intel Lab Syst 107:194-205. doi: 10.1016/j.chemolab.2011.03.011